Saturday’s Daily Piece: Insulin Pricing Federal Legislation, Insulin Price Reduction Act

Currently, both U.S. House and Senate have legislative bills, Insulin Price Reduction Act, addressing insulin pricing head on, and it is a bipartisan bill in both the House and Senate.

Most recently, Insulin Price Reduction Act, was introduced into U.S. House of Representatives by Representatives Diana DeGette (CO) and Tom Reed (NY). The key points are listed below.

-Reduce the list price of most insulin products by more than 75%.

-Require Medicare and all private insurers to cover insulin with no deductibles.

-Protect pharmaceutical companies who reduce their prices from pressure of having to offer additional rebates.

-Prohibit insurers from refusing to cover any insulin product that’s been priced at, or below, its 2006 list price.

For additional information, please click on the links below.

https://degette.house.gov/media-center/press-releases/degette-unveils-new-bipartisan-legislation-to-cut-skyrocketing-cost-of

https://degette.house.gov/sites/degette.house.gov/files/DEGETT_043_xml.pdf

In the U.S. Senators, Senators Tom Carper (DE), Jeanne Shaheen (NH), Susan Collins (Maine) and Kevin Kramer (ND) introduced a similar bill, Insulin Reduction Price Bill.

This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#insulin #reduction #bill #bipartisan #bill #federal

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.

Wednesday’s Daily Piece: Novel Renal Indication for Invokana

This week, FDA has approved an additional novel indication for canagliflozin (Invokana) for persons with type 2 diabetes and diabetes related kidney disease. Specifically, canagliflozin is now indicated to reduce worsening kidney function, risk of end stage renal disease, cardiovascular death and heart failure hospitalization in adults living with type 2 diabetes and kidney disease. Wow! Please click below to learn more.

https://www.medscape.com/viewarticle/919184?nlid=131848_3901&src=wnl_newsalrt_190930_MSCPEDIT&uac=293412PG&impID=2113721&faf=1

This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#canagliflozin #novel #kidney #indication

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.

Wednesday’s Daily Piece: Novel Agent, Imeglimin, for Type 2 Diabetes

Recently, findings from phase 3 trial for first in class novel drug, imeglimin, were presented were presented at EASD meeting in Spain. This drug works to improve mitochondrial function which improves insulin sensitivity and secretion, and decreasing hepatic/liver glucose production (now that it is a great triple action). Results from phase 3 trial in Japan are very positive. Imeglimin is the first in new novel “glimin” class of glucose lowering agents. Now, it is important to keep in mind the medication was studied in Japanese population so it remains to be seen its benefit in other populations. Sound interesting? Please click below to learn more.

https://www.medscape.com/viewarticle/918670

This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#imeglimin #novel #drug #diabetes

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.

Game Changing Week in Diabetes: Oral GLP- 1 Agonist and New Pro CGM

Boy! What an exciting week it has been in the diabetes realm! Here in the states, FDA approved oral semaglutide (Rybelsus), first ever oral GLP-1 agonist. How exciting for those living with type 2 diabetes who have avoided GLP-1 agonist because it is an injection as they have an oral option. This is a game changer. It will be available in 7 mg and 14 mg. Costs are not available at this time however there will be a savings card program. Rybelsus will be available in fourth quarter 2019.

https://www.novonordisk-us.com/media/news-releases.html?122973

In Europe, Medtronic received approval for a new disposable, factory calibrated professional CGM (Envision Pro). This eliminates the need for finger stick calibration. Envision Pro will be available in Europe and Middle East this fall. I am counting the days until we get FDA approval for this professional CGM here in the states.

http://newsroom.medtronic.com/news-releases/news-release-details/medtronic-introduces-envisiontm-pro-continuous-glucose?utm_source=Closer+Look+Subscribers+2018&utm_campaign=32e4700141-2019-09-17_%28HTML_LINKS%2909_17_2019&utm_medium=email&utm_term=0_c55d924bf1-32e4700141-412262441

This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#oral #semaglutide #EnvisionPro

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.

Blog: Developing Your Advocacy Plan

III Part Series: Advocacy

Part III: Developing Your Advocacy Plan

So, you did your preparation for your in-person meeting, and the preparation paid off because you had a great meeting with the legislator and/or staff.  You felt they truly listened to you, asked insightful questions, and remained engaged throughout the meeting.  You offered to serve as a knowledge expert for the staff and be available as a resource. 

Well, you are done now and can move on your next project, right? 

Not so fast!

Ongoing follow-up is necessary for successful advocating.  Recall the last handwritten note you received and how much it meant to you?  What a lasting impression you will leave with the legislator and staff with a simple handwritten note.  Yes, a thank you email is ok, but take the extra step of a thoughtful gracious handwritten thank you note.  Additionally, reaching out every couple of months to stay in touch with the staffer and keeping them updated is vital in growing the relationship into an established long term one. Make sure to also sign up for your legislator’s newsletter so you better understand their areas of priority and perspective.  Now that you have mailed your handwritten thank you notes, what next steps do you need to do?  Staying up to date with current and future legislation is a must as the political and legislative landscape is constantly changing.  Remember, both state and federal legislation directly impact the lives of those living with or at risk for diabetes.  Subscribe to legislative/advocacy forums through AADE and ADA to keep your knowledge up to date on legislation impacting those living with or caring for those living with diabetes. 

I, just as many others do in their advocacy work, sometimes wonder whether I am truly making a difference even after writing handwritten note and signing up for the legislators’ newsletter.  Recently, even after two visits with a legislator’s staff member and proper follow up, I walked away without their support as a co-sponsor of a diabetes related bill.  Am I giving up? Not all as this only strengthens my resolve. Also, the legislator is now more educated on diabetes.  At both federal and state levels of government bills often take multiple tries to final pass the appropriate committees, chambers and garner the needed approvals prior to ending up on a Governor’s or President’s desk for signing.  Our role is to educate, educate, educate – If we do, then those individuals living with diabetes will be heard and eventually our consistency will payoff!

Don’t go at it alone!  Network and join others who are advocating.  A great way to do this is participating in Advocacy Days through AADE, ADA, Diabetes Patient Advocacy Coalition and JDRF.  Below I have provided links to each of the previously mentioned organizations’ advocacy webpage.

https://www.diabeteseducator.org/advocacy

https://www.diabetes.org/advocacy

https://diabetespac.org/

Advocacy

Image result for advocacy diabetes
This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#advocacy #AADE #ADA #JDRF #diabetespac

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.

Thursday’s Daily Piece: New Glucagon Prefilled Injection Option FDA Approved

Great news! Xeris’ Pharmaceuticals prefilled glucagon injection, Gvoke, has been FDA approved for severe hypoglycemia. Patients will now have another glucagon treatment option in particular to the old school glucagon injection. Prefilled syringe option will be available within next 4 – 6 weeks followed by the autoinjector in early 2020. To learn more, please click below.

https://www.medscape.com/viewarticle/918102

This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#glucagon #prefilled #autoinjector

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.

Saturday’s Daily Piece: Financial Savings: Unlimited Test Strips and Insulin Savings from Novo Nordisk

Affordability of healthcare continues to be change particularly for persons living with chronic health conditions. Discounts and savings programs are ALWAYS welcomed. DiaTribe recently published an article providing details for unlimited glucose test strips at a fixed monthly rate through mySugr, One Drop, DarioHealth and Livongo. Please click below to get the details (and subscribe to DiaTribe as they publish amazing articles).

https://diatribe.org/how-get-unlimited-test-strips-and-personal-diabetes-coaching?utm_source=diaTribe&utm_campaign=9e060716e4-EMAIL_CAMPAIGN_2019_08_26_11_15&utm_medium=email&utm_term=0_22467a8528-9e060716e4-152660205

NovoNordisk has announced new cash discount program for its insulin products (NovoLog, Tresiba, Levemir) – $99 for a months’ supply (available in January 2020). Additionally, they are releasing new NovoLog and NovoLog mix follow on brands (authorized generic) at price of $279.41 for 5 pens – half cost of branded product.

https://www.novonordisk-us.com/media/news-releases.html?122971&utm_source=Closer+Look+Subscribers+2018&utm_campaign=37cd46968c-2019-09-06_NN_affordability_programs09_06_2019&utm_medium=email&utm_term=0_c55d924bf1-37cd46968c-412262441

This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#unlimited #test strips #insulin #savings

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.

Wednesday’s Daily Piece: Updated European Guidelines for Diabetes, Prediabetes and Cardiovascular Disease

Diabetes does not occur in a silo rather with other chronic diseases particularly cardiovascular. Therefore, it makes since guidelines should ideally should address both cardiovascular and diabetes. European Society of Cardiology collaborated with European Association for the Study of Diabetes in the development of principles to guide treatment of these chronic conditions. Europe is ahead of the game. To learn more details of these guidelines, please click below.

https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehz486/5556890

This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#EASD #ESC #cardiovascular #diabetes #prediabetes #guidelines

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.

Daily Piece: Hypoglycemia Risk Associated with Tramadol

Tramadol, a pain medicine with low abuse potential, is commonly prescribed in the U.S. A retrospective analysis recently found an association of hypoglycemia with tramadol use as compared to other pain medications . To learn more about this analysis, please click below.

https://www.nature.com/articles/s41598-019-48955-y

This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#hypoglycemia #tramadol #association

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.

Daily Piece: Dapagloflozin Benefit in Heart Failure

In persons with diabetes, we are concerned about cardiovascular (heart) disease and seek to prevent it. GLP-1 receptor agonists and SGLT-2 inhibitors are two drug classes that have proven their benefit in persons with type 2 diabetes with or without heart disease. It is worth noting that some drugs within each of these classes work better than others when it comes to preventing primary and secondary heart related events. Within the SGLT-2 inhibitor drug class, canagliflozin and empagliflozin have proven their heart related benefits. Well now, dapagliflozin is proving its benefit for persons with type 2 diabetes with cardiovascular (heart) disease. Just this week, results from phrase III trial (DAPA-HF) revealed dapagliflozin decreased risk of cardiovascular (heart related) death and decreased worsening of heart failure in persons with heart failure with reduced ejection faction with or without diabetes. If you want more details on this trial, please click below.

https://www.astrazeneca.com/media-centre/press-releases/2019/farxiga-met-primary-endpoint-in-landmark-phase-iii-dapa-hf-trial-for-the-treatment-of-patients-with-heart-failure-20082019.html

Image result for heart failure
This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#heart #failure #cardiovascular #death #reduction #dapagliflozin

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.